[O1] Oral Session 1　Gastrointestinal Cancer 1（Upper GI Tract）
【E】

[O1-2] The effectiveness of subsequent taxanes after nivolumab therapy in patients with advanced ESCC in ATTRACTION-3

^○Shun Yamamoto¹, Keisho Chin², Masanobu Takahashi³, Shigenori Kadowaki⁴, Yutaro Kubota⁵, Yusuke Amanuma⁶, Morihito Okada⁷, Mitsuro Kanda⁸, Yasue Kimura⁹, Yuhiko Nogi¹⁰, Yuko Arimitsu¹¹, Yuko Kitagawa¹² (1.Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 2.Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3.Department of Medical Oncology, Tohoku University Hospital, 4.Department of Clinical Oncology, Aichi Cancer Center Hospital, 5.Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 6.Department of Clinical Trial Promotion, Chiba Cancer Center, 7.Department of Surgical Oncology, Hiroshima University, 8.Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, 9.Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 10.Department of Oncology Medical, Bristol-Myers Squibb, 11.Department of Oncology Medical Affairs, ONO Pharmaceutical Company, 12.Department of Surgery, Keio University School of Medicine)